Global

Novel Recombinant Hemophilia Treatments

Latest News

  • Press Release: FDA Grants IDELVION® 7 Years of Marketing Exclusivity
  • Press Release: European Commission Approves IDELVION® for Hemophilia B
  • Press Release: EMA Supports Maintaining Orphan Designation for IDELVION®
  • Press Release: IDELVION® for Hemophilia B Now Available in the US
  • Press Release: IDELVION® for Hemophilia B Receives FDA Approval
  • Press Release: IDELVION® Receives Positive CHMP Opinion
  • Press Release: rVIII-SingleChain Marketing Authorization Application Submitted to EMA
  • Press Release: rIX-FP for Hemophilia B New Drug Application Submitted to Japan’s PMDA
  • Press Release: rIX-FP for Hemophilia B Phase III Data Presented at ASH
  • Press Release: rIX-FP and rVIII-SingleChain Data to be Presented at ASH
  • Press Release: First Patient Enrolled in rVIIa-FP Phase II/III Clinical Study
  • Press Release: rVIII-SingleChain for Hemophilia A BLA Accepted for Review by FDA
  • Press Release: rIX-FP for Hemophilia B MAA Accepted for Review by Swissmedic

CSL Behring’s recombinant factor development pipeline is built on its strength in protein research and development and scientific expertise in bleeding disorders, coupled with a long-standing commitment to the bleeding disorders community.

rVIII-SingleChain
rVIII-SingleChain for hemophilia A is a novel recombinant single-chain factor VIII (FVIII) construct specifically designed for greater molecular stability.

rVIII-SingleChain Fact Sheet

Depiction of rVIII-SingleChain molecule
Factor-rIX-FP
rIX-FP for hemophilia B is CSL Behring’s long-acting recombinant fusion protein linking coagulation factor IX with albumin. CSL Behring specifically engineered rIX-FP to extend the half-life of recombinant factor IX through genetic fusion with recombinant albumin. CSL Behring selected albumin as its recombinant genetic fusion partner for its coagulation factor proteins due to its long physiological half-life.

rIX-FP Fact Sheet

Depiction of rIX-FP molecule

These two potential therapies underscore CSL Behring’s promise to save lives and improve the quality of life for people with bleeding disorders and other serious medical conditions.

CSL Behring’s Commitment to Delivering Innovative Protein-Based Therapies and Support Programs for the Bleeding Disorders Community

"CSL Behring’s rIX-FP for Hemophilia B"
This video highlights CSL Behring’s product promise to the hemophilia B community. With a company history spanning more than 100 years, CSL Behring has always been motivated by innovation, and is the original expert in bleeding disorders.
"Hemophilia Won't Hold Me Back"
Each year, kids with hemophilia or von Willebrand disease in the U.S. come together at the Gettin’ in the Game℠Junior National Championship (JNC) program. Sponsored by CSL Behring, the JNC gives kids the opportunity to form life-long connections, learn how to safely and confidently play sports, and compete in a golf or baseball competition.
“Living with von Willebrand Disease: Jordan’s Story”
College student and Gettin' in the Game℠: Junior National Championship (JNC) mentor Jordan Swoape talks about living with von Willebrand disease and shares an inspirational message to empower others living with bleeding disorders.
Kristin's Story: Living Life to the Fullest Despite VWD
Wife, mother and caregiver Kristin Prior was diagnosed with von Willebrand Disease (VWD) after learning her son was born with the hereditary bleeding disorder. Learn about Kristin's active life despite the challenges VWD can pose and how she partners with CSL Behring to help others diagnosed with a bleeding disorder.

Share
LinkedIn Twitter Facebook Google+